-
Mashup Score: 2
Maintenance osimertinib in unresectable stage III EGFR-mutant cancer.
Source: www.drugdevletter.comCategories: General Medicine NewsTweet
-
Mashup Score: 11Why Should a Top FDA Official Unilaterally Approve an Expensive Gene Therapy? The Case of Elevidys. - 2 month(s) ago
Peter Marks, the director of the Center for Biologics Evaluation and Research within the Food and Drug Administration (FDA), unilaterally approved Sarepta Therapeutics’ gene therapy.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Why Should a Top @US_FDA Official #PeterMarks Unilaterally Approve a $$$$$$ Gene Therapy? The Case of Elevidys. https://t.co/58VWOqo0IS via @VPrasadMDMPH & @Timothee_MD Next Q, what is his exit strategy now? Where (which pharma company) is he going to join next in his career?
-
-
Mashup Score: 7
Our paper with Vinay Prasad is now published in the Journal of Cancer Policy – and it couldn’t be more timely!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Adding Adjuvant Drugs From Distinct Breast Cancer Trials https://t.co/hEixyrKyb0 via @Timothee_MD et al @Maherjane
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 2 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @miljko: @Timothee_MD @VPrasadMDMPH Afraid to post the link, Timothée? https://t.co/OE4UOA66RP
-
-
Mashup Score: 3RANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS. - 4 month(s) ago
This is a talk I presented at the ESMO Immuno-Oncology 2024 Congress, recorded live with Vinay Prasad and the VKPrasad Lab team, followed by an engaging Q&A session!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @Timothee_MD: + my talk recorded again in front of the live audience of the @vkprasadlab ! available here: https://t.co/tNHx8Sl5ON
-
-
Mashup Score: 13Does the clinical value of a drug predict Medicare expenditures? - 4 month(s) ago
In short, the answer is negative, as we found in our study published in the Journal of Cancer Policy. Our analysis also revealed other interesting findings.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Does the clinical value of a drug predict US @MedicareGov expenditures? In short, the answer is negative https://t.co/aiLmBAoWXK via #AshleyNee @Maherjane @sib313 @NICEComms https://t.co/fiJQEK1gyG
-
-
Mashup Score: 6Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let's Reflect on These Impressive Advances. - 4 month(s) ago
Remarkable advances and remaining questions.
Source: www.drugdevletter.comCategories: General Medicine News, Oncologists1Tweet-
RT @Timothee_MD: @VPrasadMDMPH detailed here: https://t.co/GAC3byTNUg https://t.co/xz5tHCfQfQ
-
-
Mashup Score: 6Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let's Reflect on These Impressive Advances. - 4 month(s) ago
Remarkable advances and remaining questions.
Source: www.drugdevletter.comCategories: General Medicine News, Oncologists1Tweet-
RT @Timothee_MD: @VPrasadMDMPH detailed here: https://t.co/GAC3byTNUg https://t.co/xz5tHCfQfQ
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 5 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 5 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
RT @Timothee_MD: @SuyogCancer @VPrasadMDMPH worth reading our analysis, which is still accurate I think : https://t.co/LDlEPquGmS